

Market Outlook

The Nifty 50 closed at 26,052, marking a positive session within the ongoing consolidation phase. On the daily chart, the 26,100 level continues to act as an immediate hurdle and remains a key zone to watch for further upside potential. On the derivatives front, fresh Put OI build-up at the 25,900 strike highlights this level as immediate support, with strong support placed at 25,800. On the upside, the index faces resistance in the 26,100–26,200 zone. A decisive move above this range could trigger a rally towards 26,500, where significant Call OI placed.

Key Indices Update

INDEX	CLOSE	CHANGE (%)
NIFTY	26052.65	0.55
SENSEX	85186.47	0.61
BANKNIFTY	59216.05	0.54
INDIA VIX	11.97	-1.01

FII's STATISTICS


FII's F&O Data

Sector	Buy/Sell	Change in OI
Index Futures	237.15	-0.52%
Index Options	-7447.21	21.62%
Stock Futures	1182.10	0.42%
Stock Options	192.14	-1.69%

FII's & DII's Cash Segment (Rs. In Crore)

Category	Amount	MTD	YTD
FII	1580.72	-12358	-122578
DII	1360.27	50334	492784

FII's Activity in Index Future



Amt in Crores


NIFTY 50 HIGH DELIVERY STOCKS

SYMBOL	DELIVERABLE QTY	CHG IN DLY RATIO VS PREV DAY	% CHG IN TRD QTY OVER PREV DAY
HDFCBANK	14380578	6.21	-0.94
POWERGRID	11984142	4.71	-4.07
TMPV	9887864	-2.28	2.11
ETERNAL	8890505	4.73	-37.84
ICICIBANK	8255745	19.66	9.07
WIPRO	6685771	-3.19	181.15
BHARTIARTL	5651009	18.47	-32.38
BEL	5213716	0.09	-27.58
ITC	5063831	12.92	2.88
SBIN	4914972	4.75	25.73


NIFTY

Nifty	26071.00
OI (In contracts)	262052
CHANGE IN OI (%)	-2.80
PRICE CHANGE (%)	0.50
IMPLICATION	SHORT COVERING

NIFTY (CLOSE VS OI)



NIFTY OPTION CHAIN




Long Buildup

Symbol	Price	Price %	OI	OI %
TECHM	1438.6	1.00	38848	11.40
TITAGARH	874.05	0.20	10130	9.10
BLUESTARCO	1793.6	0.70	6097	7.70
SOLARINDS	13804	0.10	13079	6.50
DALBHARAT	2022.6	1.60	8484	5.50


BANKNIFTY

Banknifty	59227.40
OI (In contracts)	60026
CHANGE IN OI (%)	2.90
PRICE CHANGE (%)	0.40
IMPLICATION	LONG BUILDUP

BANKNIFTY (CLOSE VS OI)



BANKNIFTY OPTION CHAIN



Short Buildup

Symbol	Price	Price %	OI	OI %
PGEL	581.35	-0.60	17931	12.10
SAMMAANCAP	160.13	-12.40	28482	11.00
TMPV	361.7	-2.50	120172	9.60
IREDA	147.36	-0.60	14321	6.20
SRF	2794.7	-1.00	21391	6.10

Top 10 High PCR Ratio Stocks

SCRIP	PUT	CALL	P/C RATIO
VOLTAS	5449500	4454625	1.22
CANBK	148884750	127102500	1.17
PETRONET	16581600	14346100	1.16
PERSISTENT	1175200	1020800	1.15
ANGELONE	2748500	2565500	1.07
AUROPHARMA	4770700	4441250	1.07
AUBANK	7050000	6707000	1.05
BSE	10222125	9873000	1.04
BPCL	19382650	19159475	1.01
HEROMOTOCO	3630900	3590550	1.01

Top 10 Low PCR Ratio Stocks

SCRIP	PUT	CALL	P/C RATIO
KAYNES	1216600	3877000	0.31
SHREECEM	58150	186000	0.31
PAGEIND	69255	201420	0.34
TATASTEEL	120527000	349503000	0.34
BOSCHLTD	77450	206875	0.37
ONGC	21546000	58079250	0.37
FORTIS	4021475	10679500	0.38
INOXWIND	18937004	49933750	0.38
NESTLEIND	2045000	5434000	0.38
PATANJALI	4050900	10760400	0.38

NIFTY 50 SUPPORT-RESISTANCE LEVELS

SYMBOL	R1	R2	PP	S1	S2
ADANIENT	2456	2474	2437	2420	2401
ADANIPTS	1498	1508	1489	1478	1469
APOLLOHOSP	7508	7560	7425	7373	7290
ASIANPAINT	2904	2920	2895	2879	2870
AXISBANK	1276	1281	1267	1261	1252
BAJAJ-AUTO	8953	9020	8907	8840	8794
BAJAJFINSV	2058	2066	2048	2040	2030
BAJFINANCE	1015	1022	1011	1004	1000
BEL	426	429	421	418	413
BHARTIARTL	2167	2174	2156	2148	2138
CIPLA	1538	1548	1523	1513	1498
COALINDIA	383	386	381	378	376
DRREDDY	1252	1258	1245	1239	1232
EICHERMOT	6939	6988	6852	6802	6715
ETERNAL	309	312	306	304	300
GRASIM	2768	2791	2754	2732	2718
HCLTECH	1689	1717	1638	1610	1559
HDFCBANK	999	1003	992	989	982
HDFCLIFE	763	766	760	757	753
HINDALCO	797	802	794	789	786
HINDUNILVR	2462	2481	2432	2412	2383
ICICIBANK	1386	1389	1380	1377	1371
INDIGO	5802	5835	5743	5710	5651
INFY	1559	1576	1527	1510	1478
ITC	406	407	404	403	402

SYMBOL	R1	R2	PP	S1	S2
JIOFIN	306	307	305	304	303
JSWSTEEL	1172	1179	1165	1158	1152
KOTAKBANK	2113	2121	2102	2094	2082
LT	4035	4052	4008	3991	3964
M&M	3757	3790	3712	3680	3635
MARUTI	15895	16038	15806	15663	15574
MAXHEALTH	1187	1210	1146	1123	1083
NESTLEIND	1288	1295	1276	1270	1258
NTPC	328	330	327	325	323
ONGC	251	253	248	246	243
POWERGRID	276	277	274	273	271
RELIANCE	1524	1529	1518	1512	1506
SBILIFE	2011	2020	2000	1991	1979
SBIN	988	993	978	973	964
SHRIRAMFIN	826	833	822	815	811
SUNPHARMA	1798	1812	1775	1760	1737
TATACONSUM	1171	1178	1161	1154	1144
TATASTEEL	174	175	173	172	171
TCS	3173	3199	3130	3103	3060
TECHM	1454	1469	1429	1414	1390
TITAN	3955	3980	3913	3888	3846
TMPV	369	376	365	358	354
TRENT	4395	4422	4366	4339	4309
ULTRACEMCO	11746	11801	11704	11649	11607
WIPRO	249	252	245	243	238

Research Team

Name	Email ID
<i>Ajit Mishra</i>	ajit.mishra@religare.com
<i>Abhijeet Banerjee</i>	abhijeet.banerjee@religare.com
<i>Gaurav Sharma</i>	gauravsharma2@religare.com
<i>Ashwani Harit</i>	ashwani.harit@religare.com
<i>Divya Parmar</i>	divya.parmar@religare.com
<i>Rajan Gupta</i>	rajan.gupta1@religare.com
<i>Vivek Chandra</i>	vivek.chandra@religare.com
<i>Himanshu Gupta</i>	himanshu.gupta1@religare.com
<i>Vishvajeet Singh</i>	vishvajeet.singh1@religare.com

Disclaimer

Before you use this research report, please ensure to go through the disclosure inter-alia as required under Securities and Exchange Board of India (Research Analysts) Regulations, 2014 and Research Disclaimer at the following link: <https://www.religareonline.com/disclaimer>

Specific analyst(s) specific disclosure(s) inter-alia as required under Securities and Exchange Board of India (Research Analysts) Regulations, 2014 is/are as under:

Statements on ownership and material conflicts of interest, compensation– Research Analyst (RA) [Please note that only in case of multiple RAs, if in the event answers differ inter-se between the RAs, then RA specific answer with respect to questions under F(a) to F(j) below, are given separately]:

S. No.	Statement	Answer	
		Yes	No
	I/we or any of my/our relative has any financial interest in the subject company? [If answer is yes, nature of Interest is given below this table]		No
	I/we or any of my/our relatives, have actual/beneficial ownership of one percent. or more securities of the subject company, at the end of the month immediately preceding the date of publication of the research report or date of the public appearance?		No
	I/we or any of my/our relative, has any other material conflict of interest at the time of publication of the research report or at the time of public appearance?		No
	I/we have received any compensation from the subject company in the past twelve months?		No
	I/we have managed or co-managed public offering of securities for the subject company in the past twelve months?		No
	I/we have received any compensation for brokerage services from the subject company in the past twelve months?		No
	I/we have received any compensation for products or services other than brokerage services from the subject company in the past twelve months?		No
	I/we have received any compensation or other benefits from the subject company or third party in connection with the research report?		No
	I/we have served as an officer, director or employee of the subject company?		No
	I/we have been engaged in market making activity for the subject company?		No

Nature of Interest if answer to F(a) above is Yes:

..... Name(s) with Signature(s) of RA(s).

[Please note that only in case of multiple RAs and if the answers differ inter-se between the RAs, then RA specific answer with respect to questions under F(a) to F(j) above, are given below]

SS. No.	Name(s) of RA.	Signatures of RA	Serial Question of question which the signing RA needs to make a separate declaration / answer	Yes	No

Copyright in this document vests exclusively with RBL. This information should not be reproduced or redistributed or passed on directly or indirectly in any form to any other person or published, copied, in whole or in part, for any purpose, without prior written permission from RBL. We do not guarantee the integrity of any emails or attached files and are not responsible for any changes made to them by any other person.

No representations are being made about the performance or activities unless accompanied by data regarding performance, disclosures of all the risk factors, etc. and disclaimer that "Such representations are not indicative of future results